Nortrel Oral Contraceptive Tablets Recalled for Discolored Inert Remainder Tablets
Teva Pharmaceuticals is recalling 12,916 cartons of Nortrel oral contraceptive tablets nationwide due to discolored inert remainder tablets that may cause confusion. Affected lot: #100042978, expiration 7/31/2024.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: FDA Class III recall with no reported illnesses or injuries. The hazard is purely cosmetic discoloration of inert remainder tablets. Per the severity rubric, FDA Class III recalls are typically scored 1–2, and cosmetic defects score 1.
Plain-English summary
Teva Pharmaceuticals USA, Inc. is recalling 12,916 cartons of Nortrel (norethindrone and ethinyl estradiol) 0.5/35 mg tablets nationwide. The affected lot is #100042978 with an expiration date of July 31, 2024. Each carton contains three blister cards with 28 tablets per card. The recalled cartons contain discolored tablets in shades of blue mixed in with the white inert remainder tablets.
The inert remainder tablets serve as a visual marker to help patients maintain proper medication sequencing. Discolored inert tablets may cause confusion about which tablets are active versus inactive when taking their medication.
Patients currently taking Nortrel should check their blister pack for the affected lot number and expiration date. Patients should contact their pharmacist or healthcare provider if they have questions about whether their medication is part of the recall. Patients should continue taking their medication as prescribed.
The recalled product
- Product
- NORTREL (NORETHINDRONE AND ETHINYL ESTRADIOL)
- Brand
- NORTREL
- Manufacturer
- Teva Pharmaceuticals USA, Inc
- Category
- Drug — Oral Contraceptive
- Hazard
- discoloration
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 100042978
- Exp 7/31/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27